Share on LinkedInShare on LinkedIn

ARTICLE · 14 FEBRUARY 2017

FDA's Postmarket Management Of Cybersecurity In Medical Devices

By its terms, the Guidance applies to: "1) medical devices that contain software (including firmware) or programmable logic, and 2) software that is a medical device, including mobile medical applications."

United StatesTechnology

On December 28, the U.S. Food and Drug Administration issued its "nonbinding recommendations" guidance for addressing post-market cybersecurity vulnerabilities in medical devices under the title "Postmarket Management of Cybersecurity in Medical Devices."1 By its terms, the recommendations are for a "risk-based framework for assessing when changes to medical devices for cybersecurity vulnerabilities require reporting to the Agency and outlines circumstances in which FDA does not intend to enforce reporting requirements."2

By its terms, the Guidance applies to: "1) medical devices that contain software (including firmware) or programmable logic, and 2) software that is a medical device, including mobile medical applications."  It applies to legacy devices, in addition to those going onto the market.3

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from